Proton MR Spectroscopy with Choline Peak as Malignancy Marker Improves Positive Predictive Value for Breast Cancer Diagnosis: Preliminary Study
Authors:
- Lia BartellaLBLia Bartella
- Elizabeth A. MorrisEMElizabeth A. Morris
- D. David DershawDDD. David Dershaw
- Laura LibermanLLLaura Liberman
- Sunitha B. ThakurSunitha B. Thakur
- Chaya MoskowitzCMChaya Moskowitz
- Jennifer GuidoJGJennifer Guido
- Wei HuangWHWei Huang
- 1 June 2006
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 239 (3) , 686-692
Abstract
To prospectively evaluate the diagnostic performance of magnetic resonance (MR) spectroscopy in patients with suspicious lesions or biopsy-proved cancers at MR imaging by using histologic findings as the reference standard. After institutional review board approval and informed consent were obtained for this HIPAA-compliant study, breast MR spectroscopy was performed in patients with suspicious or biopsy-proved malignant lesions measuring 1 cm or larger at MR imaging. Single-voxel MR spectroscopy data were collected from a single rectangular volume of interest that encompassed the lesion. MR spectroscopy findings were defined as positive if the signal-to-noise ratio of the choline resonance peak was greater than or equal to 2 and as negative in all other cases. MR spectroscopy findings were then compared with histologic findings. A total of 56 patients (age range, 20-77 years) with 57 lesions were imaged. The median lesion size at MR imaging was 2.3 cm (range, 1-15 cm). Histologically, 31 (54%) of 57 lesions were malignant, and 26 (46%) were benign. A choline peak was present in 34 of 57 lesions (including all cancers) and in three of 26 benign lesions, giving MR spectroscopy a sensitivity of 100% and a specificity of 88%. In 40 lesions of unknown histologic type, the use of MR spectroscopy as an adjunct to MR imaging would have significantly (P<.01) increased the positive predictive value of biopsy from 35% to 82%. If biopsy had been performed only on those lesions with a choline peak at MR spectroscopy, biopsy may have been spared in 23 (58%) of 40 lesions, and none of the cancers would have been missed. Proton MR spectroscopy was successfully incorporated into breast MR imaging studies for lesions measuring 1 cm or larger. This technique may be useful in reducing the number of lesions detected at MR imaging that require biopsy.Keywords
This publication has 23 references indexed in Scilit:
- Breast MRI for Women With Hereditary Cancer RiskJAMA, 2004
- Breast Cancer Screening with MRI — What Are the Data for Patients at High Risk?New England Journal of Medicine, 2004
- Proton magnetic resonance spectroscopic imaging of human breast cancer: A preliminary studyJournal of Magnetic Resonance Imaging, 2003
- In vivo quantification of choline compounds in the breast with 1H MR spectroscopyMagnetic Resonance in Medicine, 2003
- Fast MRI-Guided Vacuum-Assisted Breast Biopsy: Initial ExperienceAmerican Journal of Roentgenology, 2003
- Characterization of Lesions of the Breast with Proton MR Spectroscopy: Comparison of Carcinomas, Benign Lesions, and Phyllodes TumorsAmerican Journal of Roentgenology, 2003
- MRI of Occult Breast Carcinoma in a High-Risk PopulationAmerican Journal of Roentgenology, 2003
- Human Breast Lesions: Characterization with Contrast-enhanced in Vivo Proton MR Spectroscopy—Initial ResultsRadiology, 2001
- MR Imaging of the Breast for the Detection, Diagnosis, and Staging of Breast CancerRadiology, 2001
- Studies of human tumors by MRS: A reviewNMR in Biomedicine, 1992